Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY6 | O43306 | 1/20 | 0.47 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.47 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.47 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.47 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.47 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.47 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.47 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.47 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.47 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.43 |
| ▸ | PNMT | P11086 | 5/20 | 0.41 |
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL587014 | 0.98 | ADCY6 (0.45) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL25574541 | 0.92 | PNMT (0.43) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL29627699 | 0.84 | MB (0.31) | — | |
| SCHEMBL12090705 | 0.77 | PNMT (0.47) | ASIC3PNMTCD44MAOBDRD2 | |
| SCHEMBL20038301 | 0.77 | PNMT (0.47) | ADCY6ADCY3ADCY9ADCY5ADCY8 | |
| SCHEMBL10067119 | 0.77 | ASIC3 (0.43) | ASIC3PNMTCD44MAOBDRD2 | |
| SCHEMBL25574634 | 0.77 | NOS3 (0.57) | ASIC3PNMTCD44MAOBDRD2 | |
| Hydrochloric Acid SCHEMBL12077907 | 0.76 | PNMT (0.46) | ASIC3PNMTCD44MAOBDRD2 | |
| Hydrochloric Acid SCHEMBL30062686 | 0.76 | PNMT (0.46) | ASIC3PNMTCD44MAOBDRD2 | |
| SCHEMBL30524466 | 0.75 | ASIC3 (0.39) | ADCY6ADCY3ADCY9ADCY5ADCY8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2026-05-26 | — | — | US | disclosed |
| US-20240067637-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA ALPHA 5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2024-02-29 | — | — | US | disclosed |
| US-20240067637-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA ALPHA 5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2024-02-29 | — | — | US | disclosed |
| EP-4126859-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-C]PYRIDAZINE DERIVATIVES AS GABAA ALPHA5 RECEPTOR MODULATORS | Richter Gedeon Nyrt. (HU) | 2023-02-08 | — | — | EP | disclosed |
| CN-115348962-A | As GABA A Naphthyridines and pyrido [3,4-c ] of alpha 5 receptor modulators]Pyridazine derivatives | 吉瑞工厂 | 2022-11-15 | — | — | CN | disclosed |
| WO-2021191838-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2021-09-30 | — | — | WO | disclosed |
| EP-1831199-B1 | MMP inhibitors | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-20100256166-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256166-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-07 | — | — | US | disclosed |
| US-7700604-B2 | Hydantoin derivatives as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-7700604-B2 | Hydantoin derivatives as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-7655664-B2 | Hydantoin derivatives as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-7655664-B2 | Hydantoin derivatives as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080032997-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-02-07 | — | — | US | disclosed |
| US-20080032997-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-02-07 | — | — | US | disclosed |
| WO-2006065216-A1 | NOVEL HYDANTOIN DERIVATIVES AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065215-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256166-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | ADCY6 2072/4885ADCY3 2222/4885ADCY9 1598/4885 |
| US-20080032997-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | ADCY6 2072/4885ADCY3 2222/4885ADCY9 1598/4885 |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | GABRA5, GABRA1, GABRB1 | ADCY6 2284/4885ADCY3 1622/4885ADCY9 1926/4885 |
| US-20240067637-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA ALPHA 5 RECEPTOR MODULATORS | GABRA5, GABRA1, GABRA3 | ADCY6 3223/4885ADCY3 2574/4885ADCY9 2771/4885 |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | ADCY6 2072/4885ADCY3 2222/4885ADCY9 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.